Dr. Jacobson on the Significance of CD19-Targeted CAR T-Cell Therapy in B-Cell Malignancies

Video

In Partnership With:

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Caron Jacobson, MD, a senior physician and medical director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

The introduction of CD19-targeted CAR T-cell therapy has transformed the treatment of patients with CD19-positive cancers, ​says Jacobson, adding that the effects of CAR T-cell therapy have been felt across hematologic malignancies.

As the​se products continue in development, research efforts are seeking ways to apply this technology to other diseases that do not express CD19​, Jacobson explains. 

With a number of ongoing clinical trials ​underway, the field is hopeful that these products will receive new ​regulatory indications so that the benefits observed in B-cell malignancies can translate to other tumor types, Jacobson concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD